Holen Sie sich die Stockscreener-App
15.95
3.63%
-0.60
Handel nachbörslich:
15.77
-0.18
-1.13%
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
14.29%
0.008
|
0.007 | 0.011 | 0.034 | 0.013 |
Operating Expenses
|
17.82%
47.15
|
57.37 | 201.16 | 50.54 | 51.54 |
| Benefits Costs and Expenses |
-
|
- | - | - | - |
| Costs And Expenses |
17.82%
47.15
|
57.37 | 201.16 | 50.54 | 51.54 |
| Operating Income/Loss |
17.83%
-47.14
|
-57.37 | -201.15 | -50.51 | -51.53 |
| Nonoperating Income/Loss |
13.84%
4.456
|
5.172 | 9.212 | 5.922 | 5.719 |
| Income/Loss From Continuing Operations Before Tax |
14.29%
0.008
|
0.007 | 0.011 | 0.034 | 0.013 |
| Income/Loss From Continuing Operations After Tax |
18.22%
-42.68
|
-52.20 | -191.94 | -44.58 | -45.81 |
|
Net Income/Loss
|
18.22%
-42.68
|
-52.20 | -191.94 | -44.58 | -45.81 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
94.99%
14.79
|
295.10 | 6.157 | 256.31 | 255.40 |
| Diluted Average Shares |
94.99%
14.79
|
295.10 | 6.157 | 256.31 | 255.40 |
| Basic Earnings Per Share |
1,506%
-2.89
|
-0.18 | -0.72 | -0.17 | -0.18 |
| Diluted Earnings Per Share |
1,506%
-2.89
|
-0.18 | -0.72 | -0.17 | -0.18 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):